Grown Rogue International (GRUSF) Cost of Revenue (2011 - 2026)
Grown Rogue International's (GRUSF) quarterly Cost of Revenue came in at $5.2 million in Q1 2026, up 37.28% year-on-year from $3.8 million in Q1 2025, and up 100.0% quarter-over-quarter from -$8358.1 billion in Q4 2025.
Grown Rogue International (GRUSF) Cost of Revenue (2011 - 2026) Analysis & Trends
Grown Rogue International's Cost of Revenue history runs 13 years deep, the most recent figure standing at $5.2 million for Q1 2026.
- On a quarterly basis, Cost of Revenue rose 37.28% year-over-year to $5.2 million in Q1 2026; TTM through Mar 2026 was -$2301491018.4 billion, a 13346765336231.92% decrease from a year earlier, with the FY2025 full-year figure at $18.3 million, up 36.64% from the prior year.
- Cost of Revenue advanced to $5.2 million in Q1 2026 per GRUSF's latest filing, from -$8358.1 billion in the prior quarter.
- Across five years, Cost of Revenue topped out at $1780.1 billion in Q3 2025 and bottomed at -$2301484440.5 billion in Q2 2025.
- The 5-year median for Cost of Revenue is $224636.0 (2023), against an average of -$153432734.6 billion.
- Biggest YoY gain for Cost of Revenue was 5170235979.08% in 2025; the steepest drop was 5278709936550273.0% in 2025.
- Year by year, Cost of Revenue stood at $1.4 million in 2022, then tumbled by 93.72% to $89210.0 in 2023, then soared by 14897.59% to $13.4 million in 2024, then slumped by 62469968.47% to -$8358.1 billion in 2025, then jumped by 100.0% to $5.2 million in 2026.
- Per Business Quant, the three latest GRUSF Cost of Revenue figures stand at $5.2 million (Q1 2026), -$8358.1 billion (Q4 2025), and $1780.1 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.01 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 641.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 2.59 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 133.40 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 2.36 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 13.80 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 586.00 Mn |
| 10 | Grown Rogue International | 99.97 Mn | 86.26 Mn | 3.96 Mn | 5.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.20 Mn |
| Mar 31, 2026 | 5.20 Mn |
| Dec 31, 2025 | -8,358.06 Bn |
| Dec 31, 2025 | -8,358.06 Bn |
| Sep 30, 2025 | 1,780.12 Bn |
| Sep 30, 2025 | 1,780.12 Bn |
| Jun 30, 2025 | -2,301,484,440.47 Bn |
| Jun 30, 2025 | -2,301,484,440.47 Bn |
| Mar 31, 2025 | 3.79 Mn |
| Mar 31, 2025 | 3.79 Mn |
| Dec 31, 2024 | 13.38 Mn |
| Dec 31, 2024 | 13.38 Mn |
| Sep 30, 2024 | 34,430.05 |
| Sep 30, 2024 | 34,430.05 |
| Jun 30, 2024 | 43,599.37 |
| Jun 30, 2024 | 43,599.37 |
| Mar 31, 2024 | 100,069.00 |
| Mar 31, 2024 | 100,069.00 |
| Dec 31, 2023 | 89,210.00 |
| Dec 31, 2023 | 89,210.00 |